NKTR | Nektar Therapeutics
Category: Consumer goods
Quick infos Headquarters: San Francisco, California, United States Trade prices Volume: Market Cap: 698.53M Prev closed: Open: High: Low: 52 week low: 52 week high: Dividends: No Dividends Next ER: November 9, 2022
Earnings History Date EPS / Forecast Revenue / Forecast March 2, 2023 November 3, 2022 -0.31 / -0.448923.63M / 22.68MBeat! August 4, 2022 -0.85 / -0.9721.59M / 22.62MMay 6, 2022 -0.49 / -0.630924.82M / 24.3MBeat! February 28, 2022 -0.79 / -0.803325.01M / 34.26Mview more
Historical Data Date Price Open High Low Vol Change ER Aug 4, 2022 4.42 4.43 4.55
4.32
1.96M -1.12% Aug 3, 2022 4.47 4.08 4.47
4.07
3.06M 10.92% Aug 2, 2022 4.03 3.74 4.03
3.72
1.90M 6.90% Aug 1, 2022 3.77 3.91 3.94
3.77
1.77M -4.8% Jul 29, 2022 3.96 4.01 4.11
3.88
2.17M -2.22% Jul 28, 2022 4.05 4.12 4.18
3.91
1.70M -1.7% Jul 27, 2022 4.12 3.98 4.12
3.87
1.91M 4.57% Jul 26, 2022 3.94 3.70 3.97
3.67
1.96M 5.91% Jul 25, 2022 3.72 3.71 3.74
3.61
1.70M 1.09% Jul 22, 2022 3.68 3.94 3.95
3.62
1.88M -7.3% view more
News
Nektar Therapeutics (NKTR) Reports Q3 Loss, Misses Revenue Estimates finance.yahoo.com Apr 18, 2022 5:35 pm
Nektar Therapeutics Reports Second Quarter 2021 Financial Results finance.yahoo.com Apr 18, 2022 4:15 pm
Nektar Therapeutics to Host Earnings Call finance.yahoo.com Apr 18, 2022 3:15 pm
Why Nektar Therapeutics Stock Is Imploding Today fool.com Apr 18, 2022 12:01 pm
Nektar (NKTR) Q3 Earnings Top, Pipeline Remains On Track finance.yahoo.com Apr 18, 2022 11:00 am
Nektar Announces New Clinical Collaboration with Merck KGaA Darmstadt, Germany and Pfizer Inc. to Combine NKTR-255, a Novel Interleukin-15 Agonist, with Avelumab in the JAVELIN Bladder Medley Study finance.yahoo.com Apr 18, 2022 9:00 am
Nektar Therapeutics Presents Clinical Data for NKTR-255 in Patients with Relapsed/Refractory Hematologic Malignancies, Including Patients with Prior CAR-T Therapy, at the 63rd American Society of Hematology (ASH) Annual Meeting finance.yahoo.com Apr 18, 2022 9:00 am Nektar's stock falls 44% after experimental therapy fails to work in melanoma patients marketwatch.com Apr 18, 2022 7:40 am
Need To Know: The Consensus Just Cut Its Nektar Therapeutics (NASDAQ:NKTR) Estimates For 2021 finance.yahoo.com Apr 18, 2022 7:20 am
Bristol Myers Squibb and Nektar Announce Update on Phase 3 PIVOT IO-001 Trial Evaluating Bempegaldesleukin (BEMPEG) in Combination with Opdivo (nivolumab) in Previously Untreated Unresectable or Metastatic Melanoma finance.yahoo.com Apr 18, 2022 6:59 am
Nektar Therapeutics (NKTR) Q4 2020 Earnings Call Transcript fool.com Apr 18, 2022 1:01 am Nektar, Bristol Myers to end development program for bempegaldesleukin/Opdivo combo seekingalpha.com Apr 15, 2022 4:45 am Nektar stops clinical trials for key cancer drug, shares tumble finance.yahoo.com Apr 14, 2022 4:42 pm Goldman screens companies with best and worst pricing power into earnings season seekingalpha.com Apr 11, 2022 7:48 pm
ProPhase Labs, Inc. (PRPH) Soars 11.2%: Is Further Upside Left in the Stock? finance.yahoo.com Apr 5, 2022 5:50 am Nektar draws more downgrades after setback for melanoma trial seekingalpha.com Mar 15, 2022 11:58 pm
Longtime biotech plots 'substantial' changes after cancer drug failure bizjournals.com Mar 14, 2022 5:43 pm
Billionaire Stanley Druckenmiller Just Dumped These 10 Stocks finance.yahoo.com Mar 1, 2022 10:43 am
Grandfield & Dodd, Llc Buys AutoZone Inc, Teledyne Technologies Inc, IAC/InterActiveCorp, ... finance.yahoo.com Feb 8, 2022 9:38 am
Nektar Therapeutics Announces Agreement with Healthcare Royalty to Sell ADYNOVATE® and MOVANTIK® Royalties for $150 Million finance.yahoo.com Apr 18, 2022 8:30 am This company doesn't provide a dividend.
Talk about Nektar Therapeutics below in comments section below. Do you think you'll buy? Do you already have active trades now?
EarningsAhead is not affiliated with and this is not an endorsement of the companies featured above. This profile is based on publicly available information and is intended to be informative in nature. Most of the datas are collected by our Data Entry and we aim to be as accurate as humanly possible.
Share it with fellow traders:
or join discussions in FB below
(
FB comments )
If you are looking for News & events, Press Release, they are available on their Investors Relations site.
Consensus BUY 50 HOLD 50 SELL 0
If you want to help pay for server cost or for improving this tool. You can send it via Paypal . More features coming soon :)
Buy on Amazon In the world of investing, slow and steady wins the race. With this mantra in mind, trusted author and finance guru Eric Tyson is back with the latest edition of the #1 bestselling book, Investing For Dummies, to help you achieve your investment goals.